Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.

A Clinical Case Study on the Long Term Respiration Management of Amyotrophic Lateral Sclerosis Patient with Respiratory Failure※

Article information

Acupunct. 2014;31(3):67-73
Publication date (electronic) : 2014 September 20
doi : https://doi.org/10.13045/acupunct.2014044
Jong Cheol Lee1,2, Ho Hyun Jeong1,2, Eun Hye Cha1,2, Man Yong Park1,2, Tae Ho Kim3, Bong Keun Song4, Il Hong Son5, Sung Chul Kim1,2,
1Department of Acupuncture & Moxibustion Medicine, Gwangju Korean Medical Hospital, Wonkwang University
2Amyotrophic Lateral Sclerosis Center, Gwangju Korean Medical Hospital, Wonkwang University
3Department of Acupuncture & Moxibustion Medicine, Bucheon Jaseng Hospital of Korean Medicine
4Department of Internal Medicine, Gwangju Korean Medical Hospital, Wonkwang University
5Department of Neurology, Sanbon Hospital, Wonkwang University
* Corresponding author : Department of Acupuncture & Moxibustion Medicine, Gwang-Ju Oriental Medical Hospital, Wonkwang University, 1140-23, Hoejae-ro, Nam-gu, Gwangju, 503-832, Republic of Korea, Tel : +82-62-670-6441 E-mail : kscndl@hanmail.net
Received 2014 August 11; Revised 2014 August 28; Accepted 2014 August 28.

Abstract

Objectives:

Amyotrophic lateral sclerosis(ALS) is a progressive neurodegenerative disorder characterized by a selective death of motor neuron, leading to respiratory insufficiency. The purpose of this study was to assess the long term respiratory management of ALS patient with respiratory failure.

Methods:

One ALS patient applying a non-invasive BIPAP ventilator as well as Korean medical treatment such as acupuncture, pharmacopuncture and herbal medicine was measured on SpO2, EtCO2, Vte(expiratorytidalvolume) for 2 years 7 months.

Results:

The SpO2, EtCO2 of ALS patient were maintained in the normal range for 2 years 7 months. The Vte of ALS patient also wasn’t worse in this study.

Conclusions:

In this study, the long term respiration management, combined administration of Korean medical treatment and non-invasive BIPAP ventilator, could be effective in ALS patient with respiratory failure.

Keywords: Amyotrophic lateral sclerosis(ALS); Respiratory failure; Non-invasive BIPAP ventilator; Oriental medical treatment; EtCO2; SpO2
Fig. 1.

The changes in Vte for respiratory management

Fig. 2.

The changes in SpO2, EtCO2 and RR for respiratory management

Respiratory Progress

Notes

※

This study was supported by a grant of the Korean Health Technology R & D Project through the Korea Health Industry Development Institute(KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HI11C2142)

References

1. Gordon Paul H. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging and Disease 2013;4(5):295–310.
2. Kim SH. Diagnosis and therapeutic strategies of amyotrophic lateral sclerosis. Hanyang Medical Reviews 2006;26(1):45–51.
3. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118(3):707–19.
4. Caroscio JT, Mulvihill MN, Sterling R, Abrams B. Amyotrophic lateral sclerosis, its natural history. Neurol Clin 1987;5(1):1–9.
5. Mulder DW. Motor neuron disease. In : Dyck PJ, Thomas PK, Lambert EH, Bunge R, eds. Peripheral neuropathy 2nd ed. 2Philadelphia PA: WB Saunders; 1984. p. 1525–36.
6. Radunovic A, Annane D, Rafiq MK, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Database of Systemic Reviews 2013;published online 28. :3.
7. Gordon PH, Corcia P, Lacomblez L, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol 2009;66(6):758–61.
8. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347(9013):1425–31.
9. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585–91.
10. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease(MND). Cochrane Database Syst Rev 2012;published online 14. :3.
11. Gordon PH, Mitsumoto H. Chapter 20 symptomatic therapy and palliative aspects of clinical care. Handb Clin Neurol Netherlands: North-Holland Pub Co.; 2008. p. 389–424.
12. Heckmatt JZ, Loh L, Dubowitz V. Night-time nasal ventilation in neuromuscular disease. Lancet 1990;335(8689):579–82.
13. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5(2):140–7.
14. Lee S, Kim S. The effects of Sa-am acupuncture treatment on respiratory phsiology parameters in amyotrophic lateral sclerosis patients: a pilot study. Evid Based Complement alternat Med 2013. published online 11. p. 9.
15. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: part 1. clinical features, pathology, and ethical issues in management. Ann Neurol 1985;18(3):271–80.
16. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344(22):1688–700.
17. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60(5):813–19.
18. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies(an evidencebased review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2009;73(24):1218–26.
19. Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O, Costello RW. Use of sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2005;171(3):269–74.
20. Baumann F, Henderson RD, Morrison SC, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph lateral sclera 2010;(1–2):194–202.
21. Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH. The effect of non-invasive positive pressure ventilation(NIPPV) on cognitive function in amyotrophic lateral sclerosis(ALS): a prospective study. J Neurol Neurosurg Psychiatry 2001;71(4):482–7.
22. Heiman-Patterson TD, Miller RG. NIPPV: a treatment for ALS whose time has come. Neurology 2006;67(5):736–7.
23. Korean acupuncture & Moxibustion Medicine Society Textbook Compailation Commitee. Korean acupuncture & moxibustion medicine Ha volume Gyeonggi: Jipmoondang; 2008. p. 197–200.
24. Heo J. Donguibogam Seoul: Yeogang Publishing Company; 1994. p. 1060–1. p. 1102–3.
25. Kim DH. Illustrations Kyokam Sa-am Do-in acupuncture Busan: Sogang; 2002. p. 475–80.
26. Wade OL. Movements of the thoracic cage and diaphragm in respiration. The Journal of physiology 1954;124(2):193.
27. Barrett Kim E, Barman Susan M, Boitano Scott, Brooks Heddwen. “35. Pulmonary Function”. Ganong's review of medical physiology 23rd editionth ed. USA: McGraw-Hill Companies, Incorporated; 2009. Cite uses deprecated parameters(587–638 help).
28. Campbell EJM. The role of the scalene and sternomastoid muscles in breathing in normal subjects. An electromyographic study. Journal of Anatomy 1955;89(3):378–86.
29. Netter FH. Atlas of human anatomy. 3rd edth ed. Icon learning systems Teterboro. New Jersey: Icon learning systems; 2003. p. 191.
30. Raper AJ, Thompson WT, Shapiro W, Patterson JL. Scalene and sternomastoid muscle function. Journal of Applied Physiology 1966;21(2):497–502.
31. De Troyer A. Respiratory muscle function. In : Gibson J, Geddes DM, Costabel U, eds. Respiratory medicine London: Saunders; 2003. p. 119–29.
32. Rakhit R, Cunningham P, Furtos-Matei A, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem 2002;277(49):47551–6.
33. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995;676(1):25–40.
34. Nguyen MD, Lariviere RC, Julien JP. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001;30(1):135–47.
35. MuDan Cai, Choi SM, Song BK, Son IH, Kim SC, Yang EJ. Scolopendra subspinipes mutilans attenuates neuroinflammation in symptomatic hSOD1G93A mice. Journal of Neuroinflammation 2013;10(1):131.
36. Lee SH, Choi SM, Yang EJ. Melittin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model. Exp Neurobiol 2014;Mar. 23(1):86–92.
37. Gammage GW, Banner MJ, Blanch PB, et al. Ventilator displayed tidal volume: what you see may not be what you get. Crit Care Med 1988;16(4):454.

Article information Continued

Copyright © 2014 KAMMS. Korean Acupuncture & Moxibustion Medicine Society. All rights reserved.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fig. 1.

Fig. 1.

The changes in Vte for respiratory management

Fig. 2.

Fig. 2.

The changes in SpO2, EtCO2 and RR for respiratory management

Table 1.

Respiratory Progress

PS (cmH2O) Vte (ml) SpO2 (%) EtCO2 (mmHg) RR (BPM)
2011. 11. 10 7 - 96 39.5 23.5
2011. 12. 12 10 1,100 97 33 15.5
2012. 01. 12 12 1,000 97 34 14.5
2012. 02. 13 12 1,050 98 32.5 14
2012. 03. 12 12 1,175 97 33.5 16.5
2012. 04. 12 12 1,200 97 35.5 14.5
2012. 05. 11 12 1,100 98 32 15
2012. 06. 13 12 1,500 97 33 14
2012. 07. 13 12 1,050 96 31.5 16
2012. 08. 13 12 1,050 96 32 16
2012. 09. 13 12 1,250 95 32 16
2012. 10. 12 12 1,350 97 28 14
2012. 11. 13 12 1,140 97 34 14
2012. 12. 13 12 1,300 96 29.5 17
2013. 01. 14 12 900 97 31 14
2013. 02. 13 12 1,800 97 35 14
2013. 03. 13 12 1,050 96 32 15
2013. 04. 11 12 1,000 97 - 16
2013. 05. 13 14 1,400 96 27 14
2013. 06. 13 14 1,500 97 28 15
2013. 07. 12 14 1,000 96 28 14.5
2013. 08. 13 14 1,325 98 29 17
2013. 09. 13 14 1,650 98 27 16
2013. 10. 14 14 1,600 98 28 17
2013. 11. 13 14 1,650 98.5 28.5 19.5
2013. 12. 13 14 1,950 99 - -
2014. 01. 14 14 1,400 98 34.5 17
2014. 02. 13 14 1,400 98 28 15
2014. 03. 13 14 1,650 99 26 15
2014. 04. 14 14 1,625 99 35 15
2014. 05. 14 14 1,550 99 28 17
2014. 06. 13 14 1,500 99 26 15
2014. 07. 14 14 1,350 94.5 24 16.5

PS : pressure support.

VTe : exhaled tidal volume.

SpO2 : peripheral oxygen saturation.

EtCO2 : end-tidal carbon dioxide.

RR : respiration rate.

If the raw data was measured a range form, it was filled in means for our convenience.